---
document_datetime: 2023-09-21 20:21:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_en.pdf
document_name: tukysa-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6763505
conversion_datetime: 2025-12-22 16:49:41.810378
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number                    | (Invented) name   | Strength     | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging                         | Pack size             |
|-----------------------------------|-------------------|--------------|---------------------------------------|---------------------------|---------------------------------------------|-----------------------|
| EU/1/20/1526/001 EU/1/20/1526/002 | TUKYSA TUKYSA     | 50 mg 150 mg | Film-coated tablet Film-coated tablet | Oral use Oral use         | blister (oPA/PVC/alu) blister (oPA/PVC/alu) | 88 tablets 84 tablets |